Target intelligence / Profile preview

Glutamate ionotropic receptor delta type subunit 1 (GRID1)

Target
GRID1
Molecular classification
Ion channel, Receptor, Ionotropic glutamate receptor (delta subclass)
01

Overview

Glutamate ionotropic receptor delta type subunit 1 (GRID1, also known as GluD1) is a member of the ionotropic glutamate receptor family, which plays a key role in the organization and function of synapses in the central nervous system[1][2][6]. Unlike classical ionotropic glutamate receptors, GRID1 does not bind glutamate as a primary ligand; instead, it forms trans-synaptic adhesion complexes, regulating the activity of NMDA and AMPA receptors and influencing both excitatory and inhibitory synaptic plasticity[1][2]. GRID1 is involved in diverse biological processes critical for brain connectivity and synaptic transmission, and genetic variants or dysfunctions in GRID1 are implicated in neurodevelopmental and neuropsychiatric disorders, including Rett syndrome and spinocerebellar ataxia 18[1][2][6]. Despite being structurally homologous to other glutamate receptors and able to form cation channels, current evidence suggests its primary roles are in synaptic signaling modulation and neuronal network organization rather than direct chemical neurotransmission. No approved drugs selectively target GRID1, and its therapeutic potential remains an area of active research[1][2].

Other names
GluD1GluD1-bGluR delta-1 subunitglutamate receptor ionotropic delta-1Delta1 glutamate receptorGluRdelta1glutamate receptor, ionotropic, delta 1KIAA1220LOC103690098
02

Mechanism of action

Not established for drugs; molecular modulation includes forming trans-synaptic adhesion complexes with neurexins and cerebellins, regulation of NMDA, AMPA, and GABA receptor activity[1][2]

03

Biological functions

Synaptic organizationSignal transductionModulation of excitatory and inhibitory synaptic plasticityRegulation of NMDA and AMPA receptor activity
04

Disease associations

Neuropsychiatric disordersRett syndromeSpinocerebellar ataxia 18Potential roles in other neurodevelopmental and neurodegenerative conditions
05

Safety considerations

No direct safety concerns established due to lack of clinically used drugs; theoretical risks could involve CNS disruption, synaptic dysfunction, or neuropsychiatric side effects[1][2]
06

Interacting drugs

None established (no FDA- or clinically used drugs directly targeting GRID1 as of September 2025)[1][2][5]
07

Biomarkers

None established for clinical use (biomarker studies are ongoing but not yet validated)[1][6]

Beyond the preview

Go deeper on Glutamate ionotropic receptor delta type subunit 1 (GRID1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate ionotropic receptor delta type subunit 1 (GRID1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call